AstraZeneca’s $3 Billion SEC-Registered Notes Offering

Davis Polk advised AstraZeneca PLC in connection with its SEC-registered shelf takedown of $850 million aggregate principal amount of 3.500% notes due 2023, $400 million aggregate principal amount of floating rate notes due 2023, $1 billion aggregate principal amount of 4.000% notes due 2029 and $750 million aggregate principal amount of 4.375% notes due 2048.

Citigroup, Deutsche Bank Securities, Goldman Sachs & Co. LLC and J.P. Morgan acted as Joint Book-Running Managers on the offering.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines for three main therapy areas of healthcare: oncology; cardiovascular, renal and metabolism; and respiratory.

The Davis Polk corporate team included partner Leo Borchardt (Picture) and associates Kate Darracott and Grace M. Cao. Counsel Alon Gurfinkel and associate Veronica Orecharova provided tax advice. Associate Jennifer Lin Ricci provided 1940 Act advice.

Simpson Thacher represented the underwriters with a team including Joseph Kaufman, Mark Brod, John O’Connell, Niyati Roy and John Loubriel (Capital Markets); Jonathan Cantor and Christopher Murray (Tax); Abram Ellis (Regulatory and Compliance); and Jennie Getsin (FINRA and Blue Sky).


Involved fees earner: Leo Borchardt – Davis Polk & Wardwell; Kate Darracott – Davis Polk & Wardwell; Grace Cao – Davis Polk & Wardwell; Alon Gurfinkel – Davis Polk & Wardwell; Veronica Orecharova – Davis Polk & Wardwell; Jennifer Lin Ricci – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: AstraZeneca;


Author: Ambrogio Visconti